MENU

Fox Chase-Temple University Hospital Bone Marrow Transplant Program Awarded FACT Reaccreditation

February 8, 2017

PHILADELPHIA (February 8, 2017) – The Fox Chase-Temple University Hospital Bone Marrow Transplant Program has received internationally-recognized reaccreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center.

By demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration, the joint program of Fox Chase Cancer Center and Temple has earned FACT reaccreditation for adult allogeneic and autologous hematopoietic progenitor cell transplantation, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation. 

FACT is an internationally-recognized accrediting body for hospitals and medical institutions offering stem cell transplant, and indicates the accredited institution has met the most rigorous standards in every aspect of stem cell therapy. This covers the entire spectrum of stem cell therapy, from clinical care to donor management, cell collection, processing, storage, transportation, administration, and cell release.

FACT-JACIE Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy transplantation. The bone marrow transplant program has been found to be in compliance with these rigorous Standards as well as governmental regulations.

“We sought FACT reaccreditation because it has evolved into an all-but-necessary qualification to be accepted and competitive in the field of cellular therapy,” said Henry C. Fung, MD, Vice Chair of Hematology at Fox Chase and director of the Fox Chase-Temple BMT Program. “We believe FACT reaccreditation will make patients aware that our facility strives to achieve the highest quality care for cellular therapy treatment.”

“We are pleased that the Fox Chase-Temple program has met the requirements of the Foundation and has been granted reaccreditation,” said Phyllis Warkentin, MD, chief medical officer of FACT.

FACT reaccreditation is attained through evaluation of submitted documentation and on-site inspection to determine if an organization is in compliance with current FACT Standards and the United States Food and Drug Administration’s current rules for Good Tissue Practice. FACT Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy.

 

About Foundation for the Accreditation of Cellular Therapy

In December 1994, the International Society for Cellular Therapy (ISCT) and the American Society for Blood and Marrow Transplantation (ASBMT) merged their Standards into a single document covering all aspects of hematopoietic cell therapy (collection, processing, and transplantation). The two societies established FACT in order to develop a voluntary Inspection and Accreditation Program based on the joint Standards.  FACT promotes quality medical and laboratory practice of cellular therapy through its peer-developed standards and voluntary inspection and accreditation program.

In 2006, FACT, in collaboration with the Joint Accreditation Committee–ISCT & EBMT (JACIE), developed international standards in the field of cellular therapy.  JACIE was founded by the European Group for Blood and Marrow Transplantation (EBMT) and the International Society for Cellular Therapy (ISCT), the two leading scientific organizations involved with cellular transplantation in Europe.

Since 2007, FACT accreditation has been used in determining the U.S. News & World report rankings of transplant centers for the "America's Best Hospitals" and "America's Best Children's Hospitals" list.

The FACT Inspection and Accreditation Program was developed by Dr. Phyllis Warkentin, Chief Medical Officer of FACT, the FACT Board of Directors, as well as the ISCT and ASBMT Regulatory and Standards Committees.  The first edition of the FACT Standards was published in September 1996, and the first inspections began in September of 1997 resulting in the first program being awarded accreditation in 1998.  

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. 
For more information, call 1-888-FOX CHASE or (1-888-369-2427).